Endocrine disruptors may explain hypospadias increase

San Francisco - Researchers have successfully induced hypospadias in mice, an accomplishment that observers say provides more compelling evidence in support of the endocrine disruptor hypothesis as an explanation for the increase in hypospadias observed over the past 30 years.

Related Videos

Related Content

Advertisement

December 16th 2024

Efficacy of sildenafil cream for FSAD maintained across patient subgroups

Hannah Clarke

Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

October 16th 2024

Is video-based research feasible for pediatric urology visits?

Francesca A. Williamson, PhD Pankaj P. Dangle, MD, MCh, FAAP

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

September 10th 2024

Data show short-term benefit of certain hormonal treatments for GSM

Hannah Clarke

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

September 6th 2024

Collaboration to advance market launch of ProVate device for pelvic organ prolapse

Hannah Clarke

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

Related Content

Advertisement

December 16th 2024

Efficacy of sildenafil cream for FSAD maintained across patient subgroups

Hannah Clarke

Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder.

July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

October 16th 2024

Is video-based research feasible for pediatric urology visits?

Francesca A. Williamson, PhD Pankaj P. Dangle, MD, MCh, FAAP

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.

March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff

“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.

September 10th 2024

Data show short-term benefit of certain hormonal treatments for GSM

Hannah Clarke

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

September 6th 2024

Collaboration to advance market launch of ProVate device for pelvic organ prolapse

Hannah Clarke

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.